Ultrasonic Tissue Ablation System Market Size & Share 2025 - 2034

Ultrasonic Tissue Ablation System Market Size

The global ultrasonic tissue ablation system market was valued at USD 519.1 million in 2024. The market is anticipated to grow from USD 557.9 million in 2025 to USD 1.2 billion in 2034, growing at a CAGR of 8.7% from 2025 to 2034. High market growth is primarily attributed to surging incidence of neurological procedures, expanding applications of these systems in non-cancer diseases and technological advancement in devices among other factors.

The growing occurrence of neurological disorders such as Parkinson’s disease, essential tremor and even brain tumors is fueling the demand for non-invasive surgical techniques. For instance, according to the data published by the National Brain Tumor Society in 2022, over 1 million Americans are currently living with some kind of brain tumors. Due to the accuracy and low impact of the procedure along with faster recovery times, ultrasonic ablation systems, especially MR-guided focus ultrasound, are becoming popular in specialized neurosurgery facilities.
 

Additionally, ultrasound ablation systems are also undergoing rapid expansion beyond the field of oncology. They are now being implemented to treat conditions such as uterine fibroids, benign prostatic hyperplasia (BPH), endometriosis, and even cardiac arrhythmias. Their use in different types of procedures improves the device's overall clinical utility and expands the target patients as well as the overall value across multiple specializations which drives market growth.
 

Further, pointers such as improvements in targeting accuracy further strengthened with real-time imaging integration (Ultrasound, MRI), development of portable systems, and automated energy modulation system among other factors have considerably enhanced procedural outcomes as well as the overall safety proving the device effectiveness. Streamlining these processes has enabled ultrasound ablation devices to make them more accessible and easier to conduct, thereby witnessing adoption in further clinical settings.
 

Ultrasonic tissue ablation system is an advanced medical device that employs high-frequency ultrasound energy to destroy or remove the targeted tissues precisely without surgical cuts. These systems create intense sound energy that uniformly heats and disrupts tissue at a designated depth, thus providing a non-invasive or minimally invasive treatment for various conditions.
 

Ultrasonic Tissue Ablation System Market Trends

• Several newly developing trends are currently shaping the growth of the global market. The growing use of non-invasive image guided surgeries such as high intensity focused ultrasound (HIFU) which enables the destruction of tissues without damaging healthy tissues, is a key market trend. This development further strengthens the more general healthcare shift towards noninvasive methods that seek to shorten the hospital admission duration and speed up recovery.
   
• In addition, adoption and integration of robotic systems and AI-powered navigation technologies are improving procedural precision and overall efficiency. Thus, enhanced targeting precision by integrating real time imaging modalities such as MRI and ultrasound with ablation systems in neurology and oncology where precise targeting of lesions or tumors is necessary.
   
• The clinical validation of ultrasonic ablation systems is being accelerated through strategic partnerships between healthcare providers and device manufacturers. These alliances offer easier access to patient populations, faster regulatory processes, and enable strategic data generation for new indications. Such partnerships are vital in expanding the market and broadening the scope for newer applications.
   
• Lastly, rise in funding in clinical research and an increase in regulatory approvals for newer indications is driving innovation and wider adoption of these devices, thus contributing to the overall market growth.
   

Ultrasonic Tissue Ablation System Market Analysis

In 2021, the global market was valued at USD 425.5 million. The following year, it saw a slight increase to USD 452.1 million, and by 2023, the market further climbed to USD 483.3 million. Based on product type, the global market is segmented into high intensity focused ultrasound (HIFU) systems, ultrasonic surgical ablation systems, and shock wave therapy systems. The HIFU segment accounted for the leading market share and was valued at USD 260.8 million in 2024.
 

• High-Intensity Focused Ultrasound (HIFU) systems are becoming more popular due to their non-invasive features and versatility in hospital settings. HIFU systems enable delicate tissue cutting without damaging the surrounding areas, therefore, it is highly applicable for sensitive regions such as the brain, prostate, and uterus.
   
• HIFU is increasingly being used in oncology for liver, kidney, and prostate cancer treatments in patients who are not operable or wish to avoid surgery. Further, in gynecology, HIFU is becoming the most popular option for uterine fibroids because of its non-invasive uterus-sparing technique.
   
• Moreover, treatment of functional disorders such as essential tremor and Parkinson’s disease is also gaining attraction in the field of neurology using MR-guided focused ultrasound.
   
• Furthermore, the growing demand for HIFU among healthcare providers stems from the combination of increasing popularity by patients, precise motion tracking technologies, and imaging advancements. Hence, all the aforementioned variables are anticipated to fuel the product adoption, thereby propelling the market growth.
   

Based on application, the global ultrasonic tissue ablation system market is categorized into gynecology, cancer, cardiovascular disease, urology, neurology, and other applications. The gynecology segment accounted for leading share in the market in 2024 and is expected to reach around USD 370.6 million in 2034.
 

• The gynecology segment is seeing strong growth in the demand for ultrasonic tissue ablation systems due to the rise in prevalence of uterine fibroids and endometriosis in women of reproductive age. Non-Invasive procedures including HIFU are gaining popularity as alternatives to traditional surgical techniques such as hysterectomy and myomectomy.
   
• In addition, women prefer HIFU due to its low pain levels, rapid recovery time, and preservation of fertility. Furthermore, there is a shift in focus towards outpatient procedures that strengthens the demand for ultrasound treatments in gynecological care.
   
• Other factors contributing to product demand include better access to imaging systems, and increased spending on healthcare services for women. The growth of these services in urban hospitals and specialized women’s health clinics is anticipated to record substantial growth over the analysis period.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the global ultrasonic tissue ablation system market is classified into hospitals, imaging centers, ambulatory surgical center, and other end users. In 2024, the hospitals segment held highest market share and is expected to showcase significant growth over the analysis period.
 

• With the increasing adoption of minimally invasive and image-guided procedures, the ultrasound tissue ablation system market is witnessing a considerable surge in demand for these devices as they are seamlessly being integrated into healthcare facilities due to their sophisticated surgical capabilities.
   
• Hospitals settings are equipped with the latest infrastructure and are leading in adopting these advanced systems. The increasing ability to treat tumors, fibroids, and other neurological disorders with minimal incisions and fast recovery periods drives the adoption of these systems.
   
• Public and private hospitals are usually the early adopters of any new technological advancement. With easy access to capital investment, multidisciplinary surgical teams, and training programs, hospitals are quick to integrate new technologies.
   
• Moreover, hospitals participating in clinical research are adopting these systems at a fast pace in a bid to enhance competitiveness. The shift toward outpatient care is highly accelerating interest in non-invasive techniques due to the reduction in required surgical time.
   
• Furthermore, the incorporation of HIFU systems into the oncology, gynecology, and neurosurgery departments validates these systems trust for their high-precision therapeutic interventions.
   

The North America ultrasonic tissue ablation system market accounted for leading share and was valued at USD 174.1 million in 2024. Increasing regulatory approvals and reimbursement policies, expanding applications in non-cancer diseases coupled with rise in awareness levels are expected to drive the regional growth.
 

The U.S. market was valued at USD 136.3 million and USD 143.6 million in 2021 and 2022, respectively. The market size reached USD 162.3 million in 2024, growing from USD 152.3 million in 2023.
 

• There is a consistent rise in demand for ultrasonic tissue ablation systems in the U.S. owing to favorable reimbursement policies and surging inclination towards non-invasive as well as minimally invasive procedures. HIFU devices are increasingly being used to treat prostate cancer, uterine fibroids, and other neurological disorders, which is driving the product adoption rate in the country.
   
• Further, the integration of real-time imaging techniques enhances the accuracy and safety of these procedures for both patients and healthcare providers in order to improve patient outcomes, reduce recovery time as well as procedural complications.
   
• Moreover, the clinical and industrial collaboration between the device manufacturer and healthcare provider being formed are broadening the scope of ultrasonic ablation systems. Hence, the increased focus on value-based care systems, delivery frameworks, and patient-centric models in the U.S. healthcare system are anticipated to fuel the demand for these systems.
   

Europe ultrasonic tissue ablation system market accounted for significant revenue share and was valued at USD 152.6 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• An increase in the elderly population, number of cancer cases, and the use of non-invasive surgical procedures in gynecology are some of the reasons fueling the growth of ultrasonic tissue ablation systems in Europe. Countries such as France, Netherlands, and Italy among others are in the process of advancing reimbursement frameworks for HIFU therapies.
   
• In addition, the region’s strong focus on medical innovation and research enables the hospitals to adopt the new advanced ablation systems. Care providers in the region are also actively taking part in multi-regional clinical studies, especially those targeted at neurology and prostate cancer.
   
• Further, Europe has strong public health systems along with supportive regulatory policies which make it a favorable location for early adoption of MRI and ultrasound-guided ablation devices.
   

The Germany ultrasonic tissue ablation system market is expected to witness considerable growth over the analysis period.
 

• Due to the advanced healthcare infrastructure, the country has strong demand for neurosurgical and urological services, driving the adoption of ultrasonic tissue ablation systems. Integration of advanced imaging modalities with these systems for various therapeutic procedures a among a key growth factor supporting industry growth.
   
• Hospitals, specialty clinics and imaging centers in the country participate in a range of technological partnerships and clinical adoption projects, supporting cross-institutional adoption across academic centers. Furthermore, shifts in patient preferences towards less invasive fibroid-removing procedures along with reduced hospital stays is fueling the demand for gynecological procedures. Moreover, supported reimbursement policy changes and innovation-focused procurement models are other attributes propelling the industry growth.
   

The Asia Pacific ultrasonic tissue ablation system market is anticipated to grow at the highest CAGR of 7.8% during the analysis timeframe.
 

• Asia Pacific countries are witnessing rapid growth in the usage of ultrasonic ablation systems. This growth comes with the increasing prominence and fibroid related disorders in most populated countries.
   
• Additionally, the focus of regional manufacturers on developing affordable ablation systems designed with local market considerations, supportive government initiatives in medical technology, coupled with training programs for clinicians are further boosting the demand in this region.
   
• Further, growing urbanization coupled with advanced imaging facilities have resulted in increased use of these systems in hospitals as well as tertiary care centers. Countries such as Japan and South Korea are among the early adopters of these technologies, particularly in HIFU for gynecological and liver cancer.
   

China ultrasonic tissue ablation system market is predicted to grow significantly over the forecast period.
 

• China plays a key role in the global ultrasonic tissue ablation systems industry owing to its local consumption and availability of HIFU systems. The country has pioneered in the ultrasound-guided HIFU for gynecology and liver surgery.
   
• In addition, adoption of these systems has been fueled by government-sponsored health policy reforms, including the expansion of cancer screening services to a large number of Tier I and Tier II hospitals, as well as guidelines on the treatment of cancer (non-invasive surgery) at those hospitals.
   
• Several Chinese manufacturers have a key position in the production of low-cost HIFU systems. The country also hosts various clinical research centers that nurture local inventions. Thus, the demand for devices is also fueled by growing health consciousness and preferences for outpatient services among the urban population.
   

Brazil is experiencing significant growth in the Latin America ultrasonic tissue ablation system market and is anticipated to record robust growth throughout the forecast period.
 

• The ultrasonic tissue ablation systems market in Brazil is witnessing increased adoption, especially in private hospitals and specialty clinics offering minimally invasive procedures. There is growing demand for the implementation of HIFU technology due to increased awareness surrounding non-invasive surgical treatment options for uterine fibroids and localized cancers.
   
• Public sector adoption is still moderate in the country, owing to budgetary limitations and lack of imaging infrastructure.
   
• In addition, the increased adoption of private insurance and partnerships with international device manufacturers is expected to close the technology gap.
   
• Moreover, the Brazilian regulatory authority is focusing on approving new medical devices that can accelerate the market development in the future.
   

Saudi Arabia ultrasonic tissue ablation system market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The demand for ultrasonic tissue ablation systems in Saudi Arabia is steadily increasing due to the government’s focus on healthcare modernization initiatives under Vision 2030.
   
• Increase in investments in modern hospitals, imaging centers and oncology centers, and an upsurge in lifestyle associated diseases such as obesity, further enhance the market prospects for non-invasive procedures.
   
• In addition, rise in awareness level, supportive reimbursement schemes coupled with the rising availability of MRI and ultrasound imaging devices, further support the application of HIFU in clinical practices.
   
• Furthermore, the training of physicians and other funded practitioners from western countries is enabling greater procedural capability in the local landscape.
   

Ultrasonic Tissue Ablation System Market Share

The global market is witnessing high competition from strategic partnerships and technological innovations. Leading industry players such as Insightec, INTEGRA, stryker, Haifu and EDAP TMS among others hold more than 55% of share in the market. Players are focusing on enhancing their technological capabilities, which is expected to provide them with an added benefit compared to their peers. For example, Insightec leads in MR-guided focused ultrasound systems for gynecological and neurological surgery, and EDAP TMS is expanding its HIFU portfolio for urological conditions, particularly prostate cancer.
 

Additionally, other firms are focusing on improving their global presence and in emerging markets and improving after-sales services. Device manufacturers are improving product approval rates by collaborating with hospitals, academic institutions, and regulatory agencies.
 

Ultrasonic Tissue Ablation System Market Companies

Few of the prominent players operating in the ultrasonic tissue ablation system industry include:

• ASTAR
• bioventus
• BRAINSONIX
• EDAP TMS
• FUSMobile
• Haifu
• INSIGHTEC
• INTEGRA
• OLYMPUS
• PROFOUND
• sonablate
• Söring
• stryker
• THERACLION
• Verasonics
   
• Insightec pioneers in its non-invasive neurosurgical treatments for essential tremor and Parkinson’s disease. The company also maintains strategic partnerships with research organizations and healthcare providers, positioning it at the forefront of image-guided, non-invasive surgery innovation.
   
• Haifu's solutions are designed for the non-invasive ablation of solid tumors, such as uterine fibroids, liver cancer, and pancreatic cancers. The company emphasizes image-guided therapy, integrating MRI and ultrasound for precise, real-time treatment monitoring. It also has a strong footprint in local Chinese market and expanding presence in over 30 countries.
   

Ultrasonic Tissue Ablation System Industry News

• In March 2025, Sonablate Corp introduced its high-intensity focused ultrasound (HIFU) technology for prostate cancer treatment at the Advanced Urological Surgery Institute (ICUA) in Spain. This expansion strengthens the company’s European footprint, enhances brand visibility, and supports its mission to offer effective, non-invasive prostate therapies globally.
   
• In September 2024, Verasonics updated its Vantage NXT Research Ultrasound System with multi-system configurations. This enhanced the system's flexibility and data accuracy, broadening its appeal to researchers and improving Verasonics' market competitiveness.
   
• In August 2024, FUSMobile’s Neurolyser XR received Health Canada approval for treating chronic low back pain from facet arthritis, enabling a non-invasive, anesthesia-free ultrasound therapy in the Canadian market. This development may enable the company to focus on its regional expansion in the coming years.
   

The ultrasonic tissue ablation system market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• High intensity focused ultrasound (HIFU) systems
  • MR-guided HIFU systems
  • Ultrasound-guided HIFU systems
• Ultrasonic surgical ablation systems
• Shock wave therapy systems

Market, By Application

• Gynecology
• Cancer
• Cardiovascular disease
• Urology
• Neurology
• Other applications

Market, By End Use

• Hospitals
• Imaging centers
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE